Clinical Trial Update: Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting. [NA]

View source ↗

Summary

Completed clinical trial of reduced exposure study using CHTP 1.2 with a confined period followed by ambulatory phase in smokers; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoking-related Disease

Drugs mentioned

• CHTP 1.2

Snippet

Sponsor: Philip Morris Products S.A. | Conditions: Smoking | NA | Status: COMPLETED | Results posted: 2019-03-06